Showing 673 news articles about New & experimental HIV treatments

Filters Content type: Editors' picks Topic: New & experimental HIV treatments

News and information about clinical trials and regulatory approval of new medications to treat HIV.

How HIV works

ART Simplification Does Not Affect Systemic Inflammation in Virologically Suppressed HIV

Editor's pick
Infectious Disease Advisor
15 June 2018
New & experimental HIV treatments

ViiV Healthcare reports positive results for landmark phase III studies for dolutegravir and lamivudine

Editor's pick
ViiV Healthcare press release
15 June 2018
New & experimental HIV treatments

Single Shot of PRO 140 mAb Cuts HIV Load in Two Thirds on Failing ART

Editor's pick
National AIDS Treatment Advocacy Project
11 June 2018
New & experimental HIV treatments

Is the World Ready for Long-Acting HIV Treatment?

Editor's pick
The Body Pro
11 June 2018
New & experimental HIV treatments

China approves Albuviritide: first domestically developed, long-acting injectable anti-HIV drug

Editor's pick
Firstpost
6 June 2018
Treatment guidelines

Phase 3 registrational data is not sufficient for roll-out of new ARVs in low- and middle-income countries

Editor's pick
HIV i-Base
15 May 2018
Side effects

Is Gilead’s Entire HIV Enterprise Built on a False Promise?

Editor's pick
Poz
10 May 2018
New & experimental HIV treatments

European CHMP Adopts Positive Opinion for Gilead’s Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide)

Editor's pick
Gilead press release
27 April 2018
Treatment guidelines

U.S. Guidelines Panel Strongly Recommends Gilead’s HIV Regimen Biktarvy

Editor's pick
Poz
4 April 2018
Pharmaceutical industry

A Cheaper Version of Truvada Is Hitting the US Market: Here's Why It Might Not Lower Costs

Editor's pick
The Body
4 April 2018
Pharmaceutical industry

Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment in the U.S.

Editor's pick
Mylan press release
3 April 2018
New & experimental HIV treatments

Ibalizumab-uiyk for HIV: What Pharmacists Should Know

Editor's pick
Pharmacy Times
27 March 2018
New & experimental HIV treatments

ViiV Healthcare gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe

Editor's pick
ViiV press release
23 March 2018
People with limited treatment options

FDA approves new HIV treatment for patients who have limited treatment options

Editor's pick
FDA
7 March 2018
New & experimental HIV treatments

CytoDyn Reports Primary Endpoint Achieved in PRO 140 Pivotal Combination Therapy Trial in HIV Infection

Editor's pick
CytoDyn press release
21 February 2018
New & experimental HIV treatments

Mylan (MYL) Announces Tentative Approval for Combination HIV Treatment DTG/FTC/TAF Under FDA's PEPFAR Program

Editor's pick
Mylan press release
20 February 2018
New & experimental HIV treatments

ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment

Editor's pick
ViiV press release
8 February 2018
New & experimental HIV treatments

US FDA approves Gilead triple HIV drug, rival files lawsuit

Editor's pick
Reuters
8 February 2018
Pharmaceutical industry

Teva Announces Exclusive Launch of a Generic Version of Reyataz® in the United States

Editor's pick
Teva press release
10 January 2018
New & experimental HIV treatments

New long-acting, less-toxic HIV drug suppresses virus in humanized mice

Editor's pick
Yale News
8 January 2018
New & experimental HIV treatments

FDA Accepts New Drug Applications for Merck’s Doravirine, the Company’s Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection

Editor's pick
Merck press release
8 January 2018
New & experimental HIV treatments

HIV Drugs in the Pipeline: Expected Approvals for 2018

Editor's pick
Infectious Disease Special Edition
31 December 2017
Treatment simplification strategies

Could we safely reduce the frequency of treatments for HIV-positive people?

Editor's pick
The Conversation
8 December 2017
New & experimental HIV treatments

FDA Approves Juluca, the First Two-Drug HIV Regimen

Editor's pick
Poz
22 November 2017